Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre

Quindós, Guillermo; Sánchez-Vargas, Luis Octavio; Villar-Vidal, María; Eraso, Elena; Alkorta, Miriam; Hernández-Almaraz, José Luis

doi:10.1016/j.ijantimicag.2007.09.010

Cited by 23 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study only 5/49 of C. albicans isolates turned out to be resistant to itraconazole, but approximately half of the C. glabrata isolates, were resistant to itraconazole and fluconazole. All C. krusei strains tested in our studies as well as in studies of other groups [6,12] were resistant to fluconazole, suggesting intrinsic resistance of these strains.…”

Section: Discussionsupporting

confidence: 70%

See 1 more Smart Citation

Susceptibility of Candida spp. clinical isolates to antimycotics and disinfectants

et al. 2010

View full text Add to dashboard Cite

Abstract:The incidence of candidiasis among immunocompromised patients and emergence of antimycotics resistant strains has increased significantly. The aims of this study were: to examine the in vitro activity of antimycotics and biocides against Candida clinical isolates; to detect cross-resistance of fungi to these preparations and to estimate whether disinfectants applied in hospital areas are active against clinical Candida isolates. In vitro susceptibility of 102 Candida isolates to eight antimycotics was examined by Etest and ATB Fungus. Sensitivity of these strains to four disinfectants and an antiseptic agent was tested according to EN 1275:2005. Amphotericin B, caspofungin and 5-fluorocytosine were the most effective antimycotics against all Candida isolates. Resistance to itraconazole and fluconazole was observed among C. krusei and C. glabrata. The MICs (Minimal Inhibitory Concentrations) for ketoconazole, voriconazole and posaconazole against Candida albicans ranged: 0.003 ->32 µg/ml and one strain was resistant to three agents tested. All analysed Candida strains were sensitive to biocides containing either chlorine, aldehyde, alcohol mixtures, glucoprotamin or chlorhexidine gluconate with isopropanol. Sensitivity to these agents was observed at concentrations lower than those concentrations recommended by manufacturers to achieve proper biocidal activity to those preparations. Our data suggest that these disinfectants can be effectively applied in clinical wards to prevent nosocomial Candida infections.

show abstract

Section: Discussionsupporting

confidence: 70%

“…strains isolated from different clinical materials to antifungal agents have been published widely [5][6][7][8][9][10][11][12][13]. However, data concerning the susceptibility of clinical yeast isolates both to antifungal drugs and fungicidal agents used for disinfection and antisepsis procedures are limited.…”

Section: Introductionmentioning

confidence: 99%

Susceptibility of Candida spp. clinical isolates to antimycotics and disinfectants

et al. 2010

View full text Add to dashboard Cite

show abstract

“…C. glabrata presents decreased antifungal susceptibility to fluconazole and other current antifungal drugs and can rapidly acquire resistance (2). Candida bracarensis and Candida nivariensis, two species closely related to C. glabrata, have been recently described (3,4), but there is scarce information on the prevalence, antifungal susceptibility patterns, and clinical significance of these cryptic species (1,(5)(6)(7).…”

mentioning

confidence: 99%

In Vitro Fungicidal Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis Evaluated by Time-Kill Studies

Gil-Alonso

Jauregizar

Cantón

et al. 2015

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Anidulafungin, caspofungin, and micafungin killing activities against Candida glabrata, Candida bracarensis, and Candida nivariensis were evaluated by the time-kill methodology. The concentrations assayed were 0.06, 0.125, and 0.5 g/ml, which are achieved in serum. Anidulafungin and micafungin required between 13 and 26 h to reach the fungicidal endpoint (99.9% killing) against C. glabrata and C. bracarensis. All echinocandins were less active against C. nivariensis. Candida glabrata follows Candida albicans as the second or third most prevalent cause of candidemia worldwide (1). C. glabrata presents decreased antifungal susceptibility to fluconazole and other current antifungal drugs and can rapidly acquire resistance (2). Candida bracarensis and Candida nivariensis, two species closely related to C. glabrata, have been recently described (3, 4), but there is scarce information on the prevalence, antifungal susceptibility patterns, and clinical significance of these cryptic species (1, 5-7). The present study aimed to determine the killing activities of echinocandins against C. glabrata, C. bracarensis, and C. nivariensis (Table 1). Strains were identified by metabolic properties (ATB ID 32C; bioMérieux, Marcy l'Étoile, France) and molecular methods, as previously described (5, 7).Caspofungin (Merck Sharp & Dohme, Madrid, Spain), micafungin (Astellas Pharma, Madrid, Spain), and anidulafungin (Pfizer SLU, Madrid, Spain) were dissolved in dimethyl sulfoxide. Further dilutions were prepared in standard RPMI 1640 medium (Sigma-Aldrich, Madrid, Spain). MICs (defined as minimum concentrations that produce Ն50 growth reduction) were determined following the M27-A3 document (8). Time-kill studies were carried out on microtiter plates for the computer-controlled microbiological incubator BioScreen C MBR (LabSystems, Vantaa, Finland) in RPMI 1640 (final volume, 200 l; inoculum, 1 ϫ 10 5 to 5 ϫ 10 5 CFU/ml). The echinocandin concentrations assayed were 0.06, 0.125, and 0.5 g/ml, which are achieved in serum after standard doses (9). Plates were incubated at 36 Ϯ 1°C without agitation. At 0, 2, 4, 6, 8, 24, and 48 h, aliquots of 6 or 10 l were removed from both the control and each test solution well, serially diluted in phosphate-buffered saline (PBS), and plated onto Sabouraud agar to determine the number of CFU per milliliter. Each experiment was performed twice for each isolate (10-13). The antifungal carryover effect was determined as formerly reported (12).Time-kill data were fitted to the exponential equation N t ϭ N 0 ϫ e kt , where t is incubation time, N t represents viable yeast cells at time t, N 0 is the starting inoculum, and k is the killing or growing rate. The goodness of fit for each isolate/drug was assessed by the r 2 value (Ͼ0.8). The times needed to achieve 50, 90, 99 and 99.9% reductions in growth (t 50 , t 90 , t 99 , and t 99.9 , respectively) were calculated from the k value, as described previously (12). Analysis of variance was performed to determine significant dif-

show abstract

“…VRC remains active against most strains of C. krusei (12,17), its efficacy being demonstrated in vitro and in clinical trials (3,10). Several authors have reported a fungistatic effect of VRC (16,26), while others have stated a fungicidal effect of this drug (1,21) against Candida.…”

mentioning

confidence: 99%

Efficacy of Triazoles in a Murine Disseminated Infection by Candida krusei

Mariné

Pastor

Serena

et al. 2009

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We evaluated the efficacies of posaconazole and voriconazole in comparison with that of amphotericin B in a systemic murine infection by Candida krusei. Posaconazole at 50 mg/kg/day and voriconazole at 40 and 60 mg/kg/day prolonged survival and reduced the fungal tissue burden in the kidneys of mice similarly to amphotericin B at 1.5 mg/kg/day and liposomal amphotericin B at 10 mg/kg/day. None of the treatments tested completely resolved the infection.

show abstract

Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre

Cited by 23 publications

References 13 publications

Susceptibility of Candida spp. clinical isolates to antimycotics and disinfectants

Susceptibility of Candida spp. clinical isolates to antimycotics and disinfectants

In Vitro Fungicidal Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis Evaluated by Time-Kill Studies

Efficacy of Triazoles in a Murine Disseminated Infection by Candida krusei

Contact Info

Product

Resources

About